Early Assessment of Anthracycline-Induced Cardiotoxicity: Usefulness of Biochemical Markers and Ventricular Function Assessment.
N/A
18 Years
70 Years
18 Years
70 Years
Not Enrolling
Both
Lymphoma, Heart Failure, Congestive
Both
Lymphoma, Heart Failure, Congestive
Trial Information
Early Assessment of Anthracycline-Induced Cardiotoxicity: Usefulness of Biochemical Markers and Ventricular Function Assessment.
Inclusion Criteria:
- Histologically proven lymphoma (Hodgkin's or non-Hodgkin's)
- Age > 18 y/o and < 70 y/o
- WHO score < or = 2
- Life expectancy > 6 mo
- Left ventricular ejection fraction > 50%
- Informed consent
Exclusion Criteria:
- Previous chemotherapy using anthracyclines
- History of radiation therapy
- History of congestive heart failure
- History of chronic renal insufficiency
- Contra indication to MR examination
- Atrial fibrillation and significant arrhythmia
- Pregnancy
Type of Study:
Observational
Study Design:
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal, Time Perspective: Prospective
Principal Investigator
Alain Manrique, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Centre Henri Becquerel
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
2005-001-CHB
NCT ID:
NCT00195897
Start Date:
October 2005
Completion Date:
Related Keywords:
- Lymphoma
- Heart Failure, Congestive
- Lymphoma
- Anthracyclines
- Heart Failure
- Radionuclide
- Magnetic Resonance Imaging
- Troponin
- Natriuretic Peptide, Brain
- Heart Failure
- Lymphoma
Name | Location |
|---|
